Accueil   Diary - News   All news Adocia obtains additional financial resources to accelerate its growth

Adocia obtains additional financial resources to accelerate its growth

 

  • Establishment of a debt financing plan for a maximum amount of 15 million euros, with IPF Partners
  • First tranche of EUR 7.5 million is subscribed immediately
  • Current cash position above EUR 39 million as of October 14, 2019

 

Lyon, France, October 14, 2019 – 7:30 am CEST - Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, today announced that it has obtained additional resources from IPF Partners to finance its growth.

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree